Association of Hydrophobic Carboxyl-Terminal Dendrimers with Lymph Node-Resident Lymphocytes.
T cells
carboxyl terminal
dendrimer
hydrophobicity
lymph node
phenylalanine
Journal
Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357
Informations de publication
Date de publication:
30 Jun 2020
30 Jun 2020
Historique:
received:
25
05
2020
revised:
22
06
2020
accepted:
22
06
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
8
7
2020
Statut:
epublish
Résumé
Delivery systems to lymph node-resident T cells around tumor tissues are essential for cancer immunotherapy, in order to boost the immune responses. We previously reported that anionic dendrimers, such as carboxyl-, sulfonyl-, and phosphate-terminal dendrimers, were efficiently accumulated in lymph nodes via the intradermal injection. Depending on the terminal structure, their cell association properties were different, and the carboxyl-terminal dendrimers did not associate with any immune cells majorly. In this study, we investigated the delivery of carboxyl-terminal dendrimers with different hydrophobicity to lymph node-resident lymphocytes. Four types of carboxyl-terminal dendrimers-succinylated (C) and 2-carboxy-cyclohexanoylated (Chex) dendrimers with and without phenylalanine (Phe)-were synthesized and named C-den, C-Phe-den, Chex-den, and Chex-Phe-den, respectively. Chex-Phe-den was well associated with lymphocytes, but others were not. Chex-Phe-den, intradermally injected at the footpads of mice, was accumulated in the lymph node, and was highly associated with the lymphocytes, including T cells. Our results suggest that Chex-Phe-den has the potential for delivery to the lymph node-resident T cells, without any specific T cell-targeted ligands.
Identifiants
pubmed: 32630042
pii: polym12071474
doi: 10.3390/polym12071474
pmc: PMC7408625
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP17K06004
Organisme : Osaka Prefecture University
ID : KAKENHI Specific Support Operation
Références
J Control Release. 2009 Dec 3;140(2):108-16
pubmed: 19686787
Int J Pharm. 2018 Sep 5;548(1):707-720
pubmed: 30012508
J Am Chem Soc. 2012 Mar 7;134(9):3965-7
pubmed: 22339432
Mol Pharm. 2012 May 7;9(5):1222-30
pubmed: 22486588
J Chem Inf Comput Sci. 1987 Feb;27(1):21-35
pubmed: 3558506
Nat Commun. 2017 Nov 23;8(1):1747
pubmed: 29170511
Front Immunol. 2019 Jul 19;10:1719
pubmed: 31379886
Eur J Pharm Sci. 2018 Sep 15;122:311-330
pubmed: 30003954
Eur J Cancer. 2009 Aug;45(12):2123-31
pubmed: 19398324
Adv Drug Deliv Rev. 2011 Sep 10;63(10-11):890-900
pubmed: 21683746
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Nanomedicine. 2015 Nov;11(8):2119-27
pubmed: 26348654
Int J Pharm. 2020 Feb 25;576:119021
pubmed: 31917298
Nat Rev Immunol. 2006 Sep;6(9):659-70
pubmed: 16932751
Bioconjug Chem. 2015 May 20;26(5):890-8
pubmed: 25865284
J Control Release. 2006 Apr 10;111(3):343-51
pubmed: 16490277
Chem Soc Rev. 2018 Jan 22;47(2):514-532
pubmed: 29154385
Magn Reson Med. 2003 Oct;50(4):758-66
pubmed: 14523962